Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1378/chest.49.1.99 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias.
CPT Pharmacometrics Syst Pharmacol
January 2025
Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Sotalol, a class III antiarrhythmic agent, is used to maintain sinus rhythm in patients with atrial fibrillation or atrial flutter (AFIB/AFL). Despite its efficacy, sotalol's use is limited by its potential to cause life-threatening ventricular arrhythmias due to QT interval prolongation. Traditionally, sotalol administration required hospitalization to monitor these risks.
View Article and Find Full Text PDFDysplasia of the tricuspid valve leading to recurrent atrial flutter and fibrillation: a case report.
Eur Heart J Case Rep
January 2025
Department of Cardiology, Klinik Landstrasse, Juchgasse 25, A-1030 Wien, Austria.
Background: Atrial flutter (AFL) is usually effectively treated by cavotricuspid isthmus (CTI) ablation. If AFL recurs despite ablation, there is risk of progression to atrial fibrillation (AF) and clinicians should consider underlying structural heart diseases. This consideration becomes especially critical when right-heart-chambers are dilated.
View Article and Find Full Text PDFAssociation between autoimmune diseases and all-cause mortality in patients with cardiac arrhythmia.
Rev Esp Cardiol (Engl Ed)
December 2024
Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China. Electronic address:
Article Synopsis
- Autoimmune diseases (ADs) are linked to a higher risk of all-cause mortality in patients with cardiac arrhythmias, particularly atrial fibrillation and ventricular tachycardia.
- The study analyzed data from over 14,000 patients, finding that those with ADs had increased mortality rates after one year of discharge.
- Statistical analyses confirmed these results, highlighting the significant risk associated with ADs in arrhythmia patients, although the association for bradyarrhythmias did not reach statistical significance.
The regional distribution of catheter ablations of atrial fibrillation and atrial flutter in Poland in 2023.
Kardiol Pol
January 2025
Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, Wrocław, Poland.
Comparing pulsed field ablation with very high-power and high-power short-duration radiofrequency ablation for atrial fibrillation: a systematic review and meta-analysis.
J Interv Card Electrophysiol
December 2024
Section of Electrophysiology, Division of Cardiology, Department of Medicine, Rush University Medical Center, 1717 W Congress Pkwy/Suite 317 Kellogg, Chicago, IL, 60612, USA.
Background: Catheter ablation is a key treatment for atrial fibrillation (AF), with high-power, very high-power short-duration and pulsed field ablation (PFA) being efficient options. However, direct comparisons between these techniques are lacking.
Objective: We performed a systematic review and meta-analysis, which included predominantly observational studies (four retrospective and one prospective study), to compare PFA and High-power short-duration (HPSD) and very high-power short-duration (vHPSD) radiofrequency (RF) ablation in patients with AF.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!